Videos

Neurology News Network for the week ending April 22, 2023. [WATCH TIME: 4 minutes]

The cofounder and chief product development officer of Zevra Therapeutics talked about the phase 1 clinical trial of KP1077 for narcolepsy and potentially using it to treat other conditions. [WATCH TIME: 5 minutes]

The director of the Feil Family Brain and Mind Research Institute at Weill Cornell Medicine talked about brain health in relation to vascular health ahead of the 2023 AAN annual meeting. [WATCH TIME: 3 minutes]

Anne Marie Morse, DO, FAASM, discusses the burden and risk factors associated with excessive daytime sleepiness and narcolepsy.

Experts provide an overview of excessive daytime sleepiness and narcolepsy.

An immunology fellow at Brigham and Women’s Hospital provided perspective on the positive impacts a new diagnostic criterion for MOGAD brings to the clinical community. [WATCH TIME: 4 minutes]

A. Gordon Smith, MD, FAAN, discusses how to assess for treatment success and why the patient perspective is so important in deciding whether to change therapies.

A. Gordon Smith, MD, FAAN, talks about how new agents and emerging data are enabling clinicians to personalize care for patients with myasthenia gravis.

Neurology experts expand on advantages and disadvantages of using FDA-approved treatment compared with other therapy options for neuromyelitis optica spectrum disorder.

Robert Shin, MD, FAAN, discusses the potential advantages of using inebilizumab over rituximab in the treatment of NMOSD.

The research fellow at the Neuroimmunology Clinic and Research Laboratory, Massachusetts General Hospital and Harvard Medical School, talked about his research of cell function in NMOSD to be presented at the upcoming AAN annual meeting. [WATCH TIME: 6 minutes]

Drs Rajesh Pahwa, Daniels Kremens and Fernando Pagan provide an overview of current treatment options for treatment of dyskinesia in patients with Parkinson’s Disease.

The expert panel highlights challenges in treatment of OFF episodes and dyskinesia together and long-term consequences of delaying treatment for dyskinesia in patients with Parkinson disease.

The vascular neurologist at Allegheny Health Network provided insight on the need to create consensus guidelines that further explain the treatment, management, and rehab of basilar artery occlusions. [WATCH TIME: 3 minutes]

The neurologist at Mayo Clinic in Jacksonville Florida spoke about early detection, prevention, and time to intervene with treatment in autoimmune encephalitis. [WATCH TIME: 5 minutes]

The research fellow at the Neuroimmunology Clinic and Research Laboratory, Massachusetts General Hospital and Harvard Medical School, talked about having safer and more specific treatments for NMOSD that are antigen-specific. [WATCH TIME: 4 minutes]

Craig Mainor and Dr Mary Ann Picone highlight the role of comprehensive care and importance of treatment adherence for people living with multiple sclerosis.

Craig Mainor, a patient with multiple sclerosis, shares the story of his diagnosis. The panel discusses the advances in diagnosis and management of multiple sclerosis in the last 30 years.

Neurology News Network for the week ending April 15, 2023. [WATCH TIME: 4 minutes]

The director of functional neurosurgery at Baptist Health provided perspective on the advances of high intensity focused ultrasound as the institution nears 100 patients treated. [WATCH TIME: 4 minutes]

The chief medical officer of QurAlis talked about the potential of QRL-201 in patients with ALS from her talk presented at the 2023 MDA conference. [WATCH TIME: 4 minutes]

The Lillehei professor in stem cell and regenerative cardiovascular medicine at the University of Minnesota talked about the potential of investigating inducted pluripotent stem cells in neuromuscular diseases at MDA’s 2023 conference. [WATCH TIME: 5 minutes]

A. Gordon Smith, MD, FAAN, discusses the findings and implications of phase 3 ADAPT trial and open-label extension study evaluating the use of efgartigimod in the treatment of patients with myasthenia gravis.

A. Gordon Smith, MD, FAAN, explores the rationale for targeting the neonatal Fc receptor and the mechanisms for efgartigimod for use in the treatment of myasthenia gravis.

Episode 33 of the AUPN Leadership Minute features Mud M Alvi, MD, of West Virginia University; and Clifton L. Gooch, MD, of the University of South Florida. [WATCH TIME: 9 minutes]

With a plethora of new treatments for NMOSD, a panel discusses safety concerns.

Experts in neurology discuss newly approved medications in the treatment of neuromyelitis optica spectrum disorder, including inebilizumab, eculizumab, and satralizumab.

A. Gordon Smith, MD, FAAN, considers how rituximab and eculizumab fit into the current standard of care for myasthenia gravis.

A. Gordon Smith, MD, FAAN, discusses the role of acetylcholine esterase inhibitors, immunosuppressive agents, IV immunoglobulin, corticosteroids, as well as newer agents in the treatment of myasthenia gravis.

The neuromuscular physician at Virginia Commonwealth University talked about the promising future of gene therapy and access to resources in Duchenne muscular dystrophy. [WATCH TIME: 5 minutes]